Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a stronger eye drop dose shield the retina after cataract surgery?

NCT ID NCT07749027

Prevention Sponsor: Muhammad Aamir Latif Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This trial tests whether a higher dose of nepafenac eye drops is better than a lower dose at preventing macular edema—a swelling of the central retina—after cataract surgery. Adults aged 18 to 60 scheduled for cataract surgery will receive either a 0.3% solution once daily or a 0.1% solution three times daily, starting the day before surgery and continuing for 60 days. The study measures changes in central macular thickness and treatment compliance to see which regimen offers better protection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nepafenac sodium ophthalmic suspension (0.1% or 0.3%)
What this could lead to
If the high-dose regimen works better, it could offer a more effective way to prevent macular edema, a common complication after cataract surgery, potentially improving visual recovery for many patients.
What could go wrong
This is a single-center study with a modest sample size, and results may not apply broadly. Also, higher doses may increase the risk of eye irritation or other side effects, and the benefit over the low dose might be small.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

176 people

The number who actually took part.

Started

Jan 2026

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Any gender * Aged 18-60 years * Planned for cataract surgery Exclusion Criteria: * Patients with clinical or optical coherence tomography (OCT) evidence of pre-existing macular edema * Uncontrolled hypertension * Diabetes mellitus * Previous stroke * Renal failure * Ischemic heart disease with unstable symptoms * Acute or chronic uveitis * Retinitis pigmentosa * Diabetic retinopathy * Age-related macular degeneration * Epiretinal membrane * Retinal vein occlusion * Glaucoma * History of intraocular surgery * Traumatic cataract * Hypersensitivity to nepafenac or other non-steroidal anti-inflammatory drugs * Using topical or systemic anti-inflammatory drugs before surgery

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cataract are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cataract Macular Edema macular retinal edema prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cataract

Contacts and locations

Locations

  • Bahawal Victoria Hospital/Quaid-e-Azam Medical College

    Bahawalpur, Punjab Province, 63100, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.